High-tech’s Marius Nacht, co-founder and Chairman of Check Point Software Technologies, is banking on Israeli bio-tech with a new investment of$2.8 million into BiondVax Pharmaceuticals.

“This investment is a vote of confidence in BiondVax and its universal influenza vaccine candidate. We are now better positioned to complete our development plans and commercialize our vaccine worldwide. This strategic partnership, together with clinical results and ongoing clinical trial collaborations in Europe and the US (NIH) will enable us to proceed confidently into Phase 3 as planned,” said Ron Babecoff, BiondVax’s Founder, President and CEO.

BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine.

Nacht’s Angels Investments firm will receive 33.8 million ordinary BiondVax shares on the Tel Aviv Stock Exchange. Following the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of the Company.

The healthcare and life science portfolio at Angels Investments is managed by aMoon Partners which is co-led by Dr. Yair Schindel and Marius Nacht.

“We see great potential in BiondVax’s universal flu vaccine. We expect that this investment is the beginning of a strong partnership with BiondVax and we look forward to doing our part in helping reduce the global morbidity and mortality caused by influenza viruses,” said Dr. Yair Schindel, aMoon co-founder.